{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:06:45Z","timestamp":1776956805363,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039167"],"award-info":[{"award-number":["DA039167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA048586"],"award-info":[{"award-number":["DA048586"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA045011"],"award-info":[{"award-number":["DA045011"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA018151"],"award-info":[{"award-number":["DA018151"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA043204"],"award-info":[{"award-number":["DA043204"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00213-023-06486-5","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T04:01:30Z","timestamp":1698033690000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys"],"prefix":"10.1007","volume":"241","author":[{"given":"C. Austin","family":"Zamarripa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally L.","family":"Huskinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Andrew","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James K.","family":"Rowlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"6486_CR1","unstructured":"Azrin NH, Holz WC (1966) Punishment. In: Honig WK (ed) Operant behavior: areas of research and application. Prentice-Hall, Englewood Cliffs, 380\u2013447"},{"key":"6486_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tips.2016.11.002","volume":"38","author":"ML Banks","year":"2017","unstructured":"Banks ML, Negus SS (2017) Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci 38:181\u2013194","journal-title":"Trends Pharmacol Sci"},{"key":"6486_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph12020095","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonist. Pharmaceuticals 12:95","journal-title":"Pharmaceuticals"},{"key":"6486_CR4","doi-asserted-by":"crossref","unstructured":"Bedini A, Di Cesare Mannelli L, Micheli L, Baiula M, Vaca G, De Marco R, Gentilucci L, Ghelardini C, Spampinato S (2020) Functional selectivity and antinociceptive effects of a novel KOPr agonist. Front Pharmacol 11: 188 10.3389","DOI":"10.3389\/fphar.2020.00188"},{"key":"6486_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(96)00698-X","volume":"317","author":"CA Bolanos","year":"1996","unstructured":"Bolanos CA, Garmsen GM, Clair MA, McDougall SA (1996) Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat. Eur J Pharmacol 317:1\u20138","journal-title":"Eur J Pharmacol"},{"key":"6486_CR6","doi-asserted-by":"crossref","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aube J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9: ra117","DOI":"10.1126\/scisignal.aai8441"},{"key":"6486_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.tips.2017.08.004","volume":"38","author":"HCS Chan","year":"2017","unstructured":"Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S (2017) Designing safer analgesics via mu-opioid receptor pathways. Trends Pharmacol Sci 38:1016\u20131037","journal-title":"Trends Pharmacol Sci"},{"key":"6486_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.110.003244","volume":"63","author":"CW Cunningham","year":"2011","unstructured":"Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63:316\u2013347","journal-title":"Pharmacol Rev"},{"key":"6486_CR9","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","volume":"10","author":"AD Dunn","year":"2019","unstructured":"Dunn AD, Reed B, Erazo J, Ben-Ezra A, Kreek MJ (2019) Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem Neurosci 10:3590\u20133600","journal-title":"ACS Chem Neurosci"},{"key":"6486_CR10","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751\u20132758","journal-title":"Psychopharmacology"},{"key":"6486_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-B","volume":"681","author":"SD Glick","year":"1995","unstructured":"Glick SD, Maisonneuve IM, Raucci J, Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147\u2013152","journal-title":"Brain Res"},{"key":"6486_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1196\/annals.1316.050","volume":"1025","author":"K Hasebe","year":"2004","unstructured":"Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M et al (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404\u2013413","journal-title":"Ann N Y Acad Sci"},{"key":"6486_CR13","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","volume":"237","author":"SL Huskinson","year":"2020","unstructured":"Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE, Freeman KB (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology 237:2075\u20132087","journal-title":"Psychopharmacology"},{"key":"6486_CR14","doi-asserted-by":"crossref","unstructured":"Huskinson SL, Platt DM, Zamarripa CA, Dunaway K, Brasfield M, Prisinzano TE, Blough BE, Freeman KB (2022) The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys. Pharmacol Biochem Behav 217:173394","DOI":"10.1016\/j.pbb.2022.173394"},{"key":"6486_CR15","doi-asserted-by":"publisher","first-page":"172702","DOI":"10.1016\/j.ejphar.2019.172702","volume":"864","author":"S Inan","year":"2019","unstructured":"Inan S, Huerta AT, Jensen LE, Dun NJ, Cowan A (2019) Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol 864:172702","journal-title":"Eur J Pharmacol"},{"key":"6486_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CCID.S55942","volume":"8","author":"S Inui","year":"2015","unstructured":"Inui S (2015) Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol 8:249\u2013255","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"6486_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5055\/jom.2016.0321","volume":"12","author":"MR Jones","year":"2016","unstructured":"Jones MR, Kaye AD, Kaye AJ, Urman RD (2016) The emerging therapeutic roles of kappa-opioid agonists. J Opioid Manag 12:101\u2013107","journal-title":"J Opioid Manag"},{"key":"6486_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/jpet.118.255661","volume":"371","author":"SW Kaski","year":"2019","unstructured":"Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA et al (2019) Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J Pharmacol Exp Ther 371:487\u2013499","journal-title":"J Pharmacol Exp Ther"},{"key":"6486_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193\u2013200","journal-title":"J Pharmacol Exp Ther"},{"key":"6486_CR20","doi-asserted-by":"publisher","first-page":"e017899","DOI":"10.1371\/journal.pone.0178991","volume":"12","author":"K Kamimura","year":"2017","unstructured":"Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S (2017) Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS ONE 12:e017899","journal-title":"PLoS ONE"},{"key":"6486_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","volume":"44","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, Muschamp JW, Cowan A, Mann M, Liu-Chen LY (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion. Neuropsychopharmacology 44:939\u2013949","journal-title":"Neuropsychopharmacology"},{"key":"6486_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","volume":"226","author":"KA MacLean","year":"2013","unstructured":"MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 226:381\u2013392","journal-title":"Psychopharmacology"},{"key":"6486_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fphar.2019.00407","volume":"10","author":"KL Mores","year":"2019","unstructured":"Mores KL, Cummins BR, Cassell RJ, van Rijn RM (2019) A review of the therapeutic potential of recently developed g protein-biased kappa agonists. Front Pharmacol 10:407","journal-title":"Front Pharmacol"},{"key":"6486_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1377595","volume":"45","author":"K Nakao","year":"2009","unstructured":"Nakao K, Mochizuki H (2009) Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (barc) 45:323\u2013329","journal-title":"Drugs Today (barc)"},{"key":"6486_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-60327-323-7_7","volume":"617","author":"SS Negus","year":"2010","unstructured":"Negus SS, Bilsky EJ, Do Carmo GP, Stevenson GW (2010) Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods Mol Biol 617:79\u201391","journal-title":"Methods Mol Biol"},{"key":"6486_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399","journal-title":"Exp Clin Psychopharmacol"},{"key":"6486_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ejp.1002","volume":"21","author":"KF Paton","year":"2017","unstructured":"Paton KF, Kumar N, Crowley RS, Harper JL, Prisinzano TE, Kivell BM (2017) The analgesic and anti-inflammatory effects of Salvinorin A analogue \u03b2-tetrahydropyran salvinorin B in mice. Eur J Pain 21:1039\u20131050","journal-title":"Eur J Pain"},{"key":"6486_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774\u2013776","journal-title":"Science"},{"key":"6486_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","volume":"72","author":"M Ranganathan","year":"2012","unstructured":"Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA et al (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry 72:871\u2013879","journal-title":"Biol Psychiatry"},{"key":"6486_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","volume":"26","author":"Z Rankovic","year":"2016","unstructured":"Rankovic Z, Brust TF, Bohn LM (2016) Biased agonism: an emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett 26:241\u2013250","journal-title":"Bioorg Med Chem Lett"},{"key":"6486_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","volume":"32","author":"SS Schattauer","year":"2017","unstructured":"Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59\u201365","journal-title":"Cell Signal"},{"key":"6486_CR32","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00213-020-05749-9","volume":"238","author":"EA Townsend","year":"2021","unstructured":"Townsend EA (2021) Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration. Psychopharmacology 238:1017\u20131028","journal-title":"Psychopharmacology"},{"key":"6486_CR33","doi-asserted-by":"crossref","unstructured":"Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology (Berl) 234: 2597-2605","DOI":"10.1007\/s00213-017-4652-3"},{"key":"6486_CR34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/S0024-3205(01)00957-2","volume":"68","author":"M Tsuji","year":"2001","unstructured":"Tsuji M, Takeda H, Matsumiya T, Nagase H, Narita M, Suzuki T (2001) The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci 68:1717\u20131725","journal-title":"Life Sci"},{"issue":"1\u201313","key":"6486_CR35","first-page":"10","volume":"320","author":"JD Urban","year":"2007","unstructured":"Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320(1\u201313):10","journal-title":"J Pharmacol Exp Ther"},{"key":"6486_CR36","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","volume":"237","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Naylor JE, Huskinson SL, Townsend EA, Prisinzano TE, Freeman KB (2020a) Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology 237:1471\u20131480","journal-title":"Psychopharmacology"},{"key":"6486_CR37","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1007\/s00213-021-05965-x","volume":"238","author":"CA Zamarripa","year":"2021","unstructured":"Zamarripa CA, Pareek T, Schrock HM, Prisinzano TE, Blough BE, Sufka KJ, Freeman KB (2021) The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats. Psychopharmacology 238:3463\u20133476","journal-title":"Psychopharmacology"},{"key":"6486_CR38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/FBP.0000000000000581","volume":"31","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Patel TR, Williams BC, Pareek T, Schrock HM, Prisinzano TE, Freeman KB (2020b) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats. Behav Pharmacol 31:792\u2013797","journal-title":"Behav Pharmacol"},{"key":"6486_CR39","doi-asserted-by":"publisher","first-page":"108244","DOI":"10.1016\/j.neuropharm.2020.108244","volume":"176","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kreek MJ (2020) Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice. Neuropharmacology 176:108244","journal-title":"Neuropharmacology"},{"key":"6486_CR40","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","volume":"288","author":"L Zhou","year":"2013","unstructured":"Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F, Cameron MD, Prisinzano TE, Aube J, Bohn LM (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288:36703\u201336716","journal-title":"J Biol Chem"},{"key":"6486_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/164_2021_443","volume":"271","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Freeman K, Setola V, Cao D, Kaski S, Kreek MJ, Liu-Chen LY (2022) Preclinical studies on nalfurafine (TRK-820), a clinically used KOR agonist. Handb Exp Pharmacol 271:137\u2013162","journal-title":"Handb Exp Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06486-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:09:17Z","timestamp":1706000957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06486-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6486"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06486-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}